HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellis, S. G. Search for Related Content PubMed PubMed Citation Articles by Ellis, S. G.

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology

Stephen G. Ellis, MD^*, A. Michael Lincoff, MD^*, Dave Miller, MS, James E. Tcheng, MD, Neal S. Kleiman, MD, Dean Kereiakes, MD^||, Robert Califf, MD, Eric J. Topol, MD^* for the EPIC and EPILOG Investigators

^* Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Department of Biostatistics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Department of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
University of Texas, Houston, Texas, USA
^|| The Christ Hospital, Cincinnati, Ohio, USA

View larger version (22K): [in a new window]   Figure 1 Treatment effect of abciximab on 30-day adverse outcome for various lesion morphologies. LL = lesion length; Deg SVG = degenerated saphenous vein graft.